Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,959,774 | $1,235,423 | $1,126,782 | $2,568,670 |
| - Cash | $72,307 | $22,954 | $45,006 | $19,522 |
| + Debt | $7,105 | $6,165 | $87,746 | $324,386 |
| Enterprise Value | $1,894,572 | $1,218,634 | $1,169,522 | $2,873,534 |
| Revenue | $167,133 | $131,314 | $196,245 | $241,544 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Gross Profit | $156,059 | $96,265 | $143,418 | $179,368 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| EBITDA | $40,794 | $100,837 | $81,204 | $142,770 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |
| Net Income | -$4,032 | $52,154 | -$33,361 | $57,138 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| % Growth | -107.5% | 248.5% | -159.3% | – |
| Operating Cash Flow | $97,047 | $49,577 | $137,850 | $78,798 |
| Capital Expenditures | -$19,640 | -$53,849 | -$17,923 | -$8,761 |
| Free Cash Flow | $77,407 | -$4,272 | $119,927 | $70,037 |